Highlights Instil Bio, Inc.

Equities

TIL

US45783C2008

Delayed Nasdaq Other stock markets 09:30:00 2024-06-07 am EDT			5-day change	1st Jan Change
10.62 ^USD	-0.50%		-0.65%	+39.37%

May. 13	Baird Adjusts Price Target on Instil Bio to $32 From $54, Maintains Outperform Rating	MT
May. 10	Instil Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Instil Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Instil Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Instil Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Instil Bio, Inc. Enters into Agreement with A Collaboration to Conduct Preclinical Manufacturing Feasibility Studies in the ITIL-306 Program	Jan. 16	CI
Instil Bio Says 1-for-20 Reverse Stock Split to Take Effect on Dec. 7	Dec. 06	MT
Instil Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Instil Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Instil Bio, Inc. Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference	23-06-26	CI
Instil Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
INSTIL BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-31	AQ
Instil Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
North American Morning Briefing : Focus This Week -3-	23-03-06	DJ
Instil Bio Announces Resumption of Clinical Trial of Costar-Til Candidate Itil-306 in Lung, Ovarian, and Renal Cancer	23-01-09	CI
INSTIL BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-11-14	AQ
Instil Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
ETF Preview: ETFs, Futures Decline Pre-Bell Ahead of Chicago Purchasing Managers Index	22-10-31	MT
Instil Bio, Inc. Pauses Enrollment in Delta-1, Phase 2 Clinical Trial of ITIL-168 in Patients with Advanced Melanoma	22-10-31	CI
Instil Bio, Inc. Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials of ITIL-168 and ITIL-306	22-10-31	CI
Instil Bio Announces First Patient Dosed with ITIL-306, First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha, in Non-Small Cell Lung Cancer	22-10-18	CI
INSTIL BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-08-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Instil Bio, Inc.

Equities

TIL

US45783C2008

Highlights

Filters